Transfer from | Medicine Guanlan
On March 20, Boshengji Pharmaceutical Technology (Suzhou) Co.
, Ltd.
(hereinafter referred to as "Boshengji Medicine") announced that the company developed a chimeric antigen receptor (CAR)-T cell injection targeting B7-H3.
(R&D code: TAA06 injection) has recently been granted orphan drug status by the US FDA for the treatment of neuroblastoma
.
The advent of CAR-T cell therapy is an important breakthrough in the field of cancer
.
Several CAR-T cell therapy products have been approved worldwide, bringing new options to many blood cancer patients
.
However, in the field of solid tumor treatment, CAR-T cell therapy products have not yet achieved breakthroughs
.
According to a press release from Boshengji Pharmaceuticals, the main reasons for the poor efficacy of CAR-T products in the field of solid tumors are that the heterogeneity of solid tumors easily leads to treatment escape, and the tumor immunosuppressive microenvironment hinders T cell homing and infiltration.
.
Neuroblastoma is one of the most common extracranial solid tumors in children with insidious onset and strong heterogeneity
.
Among them, high-risk neuroblastoma is called "the king of childhood tumors" because of its low cure rate
.
Because neuroblastoma is a low-immunogenic tumor, the effect of immunotherapy has been poor, and new treatment methods are urgently needed in clinical practice
.
In order to solve the above challenges, the R&D team of Boshengji Pharmaceuticals has developed TAA06 injection in a targeted manner
.
This is a CAR-T cell injection targeting B7-H3
.
B7-H3, a transmembrane protein of the B7 family, is frequently overexpressed in a variety of cancers including lung cancer, prostate cancer, breast cancer, etc.
, and its overexpression is associated with poor prognosis of patients, which makes B7-H3 a an interesting anticancer target
.
According to the press release, Boshengji Medicine intends to develop TAA06 injection for the treatment of neuroblastoma
.
In preclinical studies, the drug candidate has achieved good pharmacodynamic and safety data
.
In addition, Boshengji Pharmaceutical also stated in the press release that the company has successfully developed a highly optimized fully automatic preparation process, which can effectively control the cost of the product, and improve the access of ordinary children to innovative CAR-T cell drugs.
Accessibility creates the conditions
.
The orphan drug designation granted by the FDA this time is an important research progress for TAA06 injection
.
Note: Content has been deleted
Original title: Boshengji CAR-T product obtained FDA orphan drug designation, targeting neuroblastoma!
